The Role of Maintenance Therapy in Multiple Myeloma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Components of Myeloma Therapy Transplant-Eligible Patients

VRd vs Rd: SWOG S0777 Data

MM Induction Therapy

Role of Carfilzomib in Induction Therapy

Summary: Induction Therapy

Maintenance Lenalidomide: Key Trials

Meta-Analysis: HRs for OS by Risk Subgroup

HOVON-65/GMMG-HD4: Bortezomib Induction and Maintenance by Cytogenetic Risk

Implementing Maintenance Therapy in Practice

Selected Maintenance Options in Transplant-Eligible Patients

Maintenance Regimens for Transplant-Ineligible Patients

FIRST Trial: Benefit With Continuous Len in Nontransplanted MM

SWOG S0777: RVD vs RD

Summary: Maintenance Therapy

Toxicities and Maintenance Therapy

Managing Complications

Future Directions in MM

Key Takeaways